Loading
Cancer Related Molecular Pathways · Journal article
Pulmonologiya · August 12, 2026
Raises a question worth testing. It does not answer one.
This literature review summarizes existing observations of GnRH receptor presence in lung cells and reports both therapeutic potential (targeted drug delivery, inhalation administration for lung cancer) and pulmonary risks (interstitial lung disease, pneumonia) associated with GnRH analogues and antagonists. However, the authors explicitly acknowledge scarcity and inconsistency of evidence, including conflicting reports of protective versus harmful effects, and call for further fundamental and applied research rather than drawing definitive conclusions.
Narrative literature review. Not applicable; literature review discussing potential applications in lung disease and cancer patients with GnRH receptor expression.
GnRH receptors are present in various lung cells and certain cancer cells, enabling potential use of GnRH-agonists and antagonists for pulmonary disease and malignant tumors with lung metastases GnRH-conjugated cytostatics are reported to be less toxic and more effective than cytostatics alone, with inhalation administration described as promising for lung cancer treatment Interstitial lung disease is documented as a pulmonary complication of both GnRH analogues and antagonists that can be fatal
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should be aware that GnRH medications may have pulmonary effects—both potential therapeutic applications for targeted drug delivery and serious risks such as interstitial lung disease—but current evidence is insufficient to guide specific clinical decisions. The conflicting literature indicates caution is warranted and individualized assessment is necessary.
This literature review identifies potential mechanisms and conflicting observations about GnRH effects on lungs but does not present original empirical evidence, controlled comparisons, or definitive conclusions—only raising questions for future research.
As stated by the source record.
Clinicians should be aware that GnRH medications may have pulmonary effects—both potential therapeutic applications for targeted drug delivery and serious risks such as interstitial lung disease—but current evidence is insufficient to guide specific clinical decisions. The conflicting literature indicates caution is warranted and individualized assessment is necessary.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Gonadotropin-releasing hormone (GnRH) medications are used to treat a wide range of reproductive disorders. GnRH regulates not only the maturation and growth of the gonads, but also the immune system and metabolism, thereby affecting non-reproductive, somatic tissues. GnRH affects the lungs, but research findings are limited and not generalized. The aim was to summarize the effects of GnRH on the lungs based on a literature review. Results. The presence of specific receptors for GnRH (GnRHR) in various lung cells and in the cells of some forms of cancer allows the use of GnRH-agonists and antagonists for the treatment of pulmonary disease and for both malignant tumors and their metastases to the lungs, especially those originating from the reproductive organs. The presence of GnRHR in tumor cells impels binding GnRH both to antitumor drugs for their targeted delivery and to magnetic nanoparticles for magnetic resonance imaging of cancer. Various forms of cytostatics conjugated with GnRH are less toxic and more effective than the cytostatics themselves. A large surface area with good vascularization and the ability to exchange various substances allow for systemic delivery of GnRH via inhalation into the lungs. Inhalation administration of anticancer drugs associated with a GnRH analogue is promising for the treatment of lung cancer with GnRHR expression. One of the pulmonary complications that develops when using both GnRH analogues and antagonists is interstitial lung disease, which can lead to death. An increased risk of classical pneumonia has been described after androgen deprivation therapy. Also, GnRH can enhance the development of lung pathology during radiation exposure. However, some publications report the absence of negative effects of GnRH on the pulmonary system in the experiments and in clinical practice and report that an increased level of GnRH even protects the lungs from edema and inflammatory damage, reduces the severity of sclerosis and fibrosis. Pulmonary macrophages, type 1 and 2 alveolar cells can be directly involved in the degradation of GnRH and have the necessary enzyme complexes. Conclusion. The obvious scarcity and inconsistency of publications on all aspects of GnRH action on the lungs indicates the need for further continuation of not only applied research, but also fundamental research, due to the high prospects. The GnRH drugs have advantages and disadvantages. Hormonal therapy should be prescribed with caution, taking into account all indications and contraindications, as well as the endocrinologist’s experience, aiming for the most favorable long-term result.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.